[{"id":"6949986f-68ca-42ba-9f11-e6873a1fcf1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02990416","created_at":"2021-01-18T14:42:35.002Z","updated_at":"2024-07-02T16:37:27.122Z","phase":"Phase 1/2","brief_title":"A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma","source_id_and_acronym":"NCT02990416","lead_sponsor":"Angimmune LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Resimmune (VG712)"],"overall_status":"Unknown status","enrollment":" Enrollment 63","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2016-12-13"}]